Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nitin Malhotra

Interventional Pain Medicine Orland Park, IL Medical Doctor

NPI 1992970859 CMS profile 226454

16045 108Th Ave Ste C, Ste 50, Orland Park, IL 60467

Open in the dashboard

General payments

$2,399

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nitin Malhotra of Orland Park, IL is reported in the CMS Open Payments database as having received $2,399 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $320 16
2024 General $188 9
2023 General $264 9
2022 General $341 14
2021 General $261 12
2020 General $401 20
2019 General $625 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nitin Malhotra
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Nitin Malhotra were reported at $320. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Nitin Malhotra Interventional Pain Medicine median Middle half National median
2019 $625 $684 $216–$2,079 $163
2020 $401 $382 $122–$1,109 $114
2021 $261 $552 $167–$1,554 $132
2022 $341 $605 $187–$1,924 $149
2023 $264 $671 $195–$1,915 $160
2024 $188 $684 $206–$1,837 $164
2025 $320 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $560 27 payments
  2. Nevro Corp. $235 9 payments
  3. Abbott Laboratories $195 8 payments
  4. Collegium Pharmaceutical, Inc. $122 7 payments
  5. Flexion Therapeutics, Inc. $115 5 payments
  6. SI-BONE, Inc. $104 3 payments
  7. RedHill Biopharma Inc. $83 4 payments
  8. Pfizer Inc. $79 3 payments
  9. Electronic Waveform Lab, Inc. $72 1 payment
  10. AbbVie, Inc. $72 3 payments
  11. Other $762 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,378 112 payments
  2. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL PAIN MANAGEMENT $268 12 payments
  2. Senza $125 4 payments
  3. Zilretta $115 5 payments
  4. GENERAL - PAIN MANAGEMENT $113 7 payments
  5. Movantik $83 4 payments
  6. Senza Spinal Cord Stimulation System $82 4 payments
  7. BOTOX $67 3 payments
  8. IFUSE IMPLANT $63 2 payments
  9. HYMOVIS $59 4 payments
  10. XTAMPZA $52 3 payments
  11. Other $1,178 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

936

Median for Pain Management: 951

Drug cost

$15,948

Median for Pain Management: $26,034

Branded share of claims

44.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 334 $6,855
Pregabalin Generic 76 $2,361
Gabapentin Generic 134 $2,240
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 30 $1,190
Oxycodone Hcl Generic 34 $846
Morphine Sulfate Er Morphine Sulfate Brand 30 $685
Tizanidine Hcl Generic 42 $387
Tramadol Hcl Generic 106 $335
Methylprednisolone Generic 49 $291
Cyclobenzaprine Hcl Generic 43 $273

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$271,807

Of which drugs: $16,891

Medicare patients

489

Average age 75

Services billed

8,266

300 women, 189 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Diabetes 33%
Chronic kidney disease 27%
Depression 22%
COPD 21%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 17 1,560 $8,088
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 261 3,026 $2,322
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 261 660 $71
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 28 236 $21
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 48 50 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record